289 related articles for article (PubMed ID: 38274668)
1. Glucocorticoid-Induced Ocular Hypertension: Origins and New Approaches to Minimize.
Yorio T; Patel GC; Clark AF
Expert Rev Ophthalmol; 2020; 15(3):145-157. PubMed ID: 38274668
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma.
Patel GC; Millar JC; Clark AF
Invest Ophthalmol Vis Sci; 2019 May; 60(6):1967-1978. PubMed ID: 31050723
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.
Stahn C; Löwenberg M; Hommes DW; Buttgereit F
Mol Cell Endocrinol; 2007 Sep; 275(1-2):71-8. PubMed ID: 17630118
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms involved in the side effects of glucocorticoids.
Schäcke H; Döcke WD; Asadullah K
Pharmacol Ther; 2002 Oct; 96(1):23-43. PubMed ID: 12441176
[TBL] [Abstract][Full Text] [Related]
5. [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
Huisman AM; Jacobs JW; Buttgereit F; Bijlsma JW
Ned Tijdschr Geneeskd; 2006 Mar; 150(9):476-80. PubMed ID: 16553045
[TBL] [Abstract][Full Text] [Related]
6. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases.
Kato M; Hagiwara Y; Oda T; Imamura-Takai M; Aono H; Nakamura M
J Ocul Pharmacol Ther; 2011 Aug; 27(4):353-60. PubMed ID: 21574866
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands.
Löwenberg M; Stahn C; Hommes DW; Buttgereit F
Steroids; 2008 Oct; 73(9-10):1025-9. PubMed ID: 18221974
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid's pharmacology: past, present and future.
Gessi S; Merighi S; Borea PA
Curr Pharm Des; 2010; 16(32):3540-53. PubMed ID: 20977419
[TBL] [Abstract][Full Text] [Related]
9. New insights into the novel anti-inflammatory mode of action of glucocorticoids.
Ingawale DK; Mandlik SK
Immunopharmacol Immunotoxicol; 2020 Apr; 42(2):59-73. PubMed ID: 32070175
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid receptor signaling in the eye.
Sulaiman RS; Kadmiel M; Cidlowski JA
Steroids; 2018 May; 133():60-66. PubMed ID: 29129720
[TBL] [Abstract][Full Text] [Related]
11. SEGRAs: a novel class of anti-inflammatory compounds.
Schäcke H; Hennekes H; Schottelius A; Jaroch S; Lehmann M; Schmees N; Rehwinkel H; Asadullah K
Ernst Schering Res Found Workshop; 2002; (40):357-71. PubMed ID: 12355726
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204
[TBL] [Abstract][Full Text] [Related]
13. Basic sciences in clinical glaucoma: steroids, ocular hypertension, and glaucoma.
Clark AF
J Glaucoma; 1995 Oct; 4(5):354-69. PubMed ID: 19920699
[TBL] [Abstract][Full Text] [Related]
14. Animal models of glucocorticoid-induced glaucoma.
Overby DR; Clark AF
Exp Eye Res; 2015 Dec; 141():15-22. PubMed ID: 26051991
[TBL] [Abstract][Full Text] [Related]
15. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds.
Sundahl N; Bridelance J; Libert C; De Bosscher K; Beck IM
Pharmacol Ther; 2015 Aug; 152():28-41. PubMed ID: 25958032
[TBL] [Abstract][Full Text] [Related]
16. Optimized glucocorticoid therapy: teaching old drugs new tricks.
Strehl C; Buttgereit F
Mol Cell Endocrinol; 2013 Nov; 380(1-2):32-40. PubMed ID: 23403055
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects.
Du J; Cheng B; Zhu X; Ling C
J Immunol; 2011 Jul; 187(2):942-50. PubMed ID: 21666059
[TBL] [Abstract][Full Text] [Related]
18. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective.
Ayroldi E; Macchiarulo A; Riccardi C
FASEB J; 2014 Dec; 28(12):5055-70. PubMed ID: 25205742
[TBL] [Abstract][Full Text] [Related]
19. The long winding road to the safer glucocorticoid receptor (GR) targeting therapies.
Lesovaya EA; Chudakova D; Baida G; Zhidkova EM; Kirsanov KI; Yakubovskaya MG; Budunova IV
Oncotarget; 2022; 13():408-424. PubMed ID: 35198100
[TBL] [Abstract][Full Text] [Related]
20. [Current insights into the development of new glucocorticoid receptor ligands].
Buttgereit F; Song IH; Straub RH; Burmester GR
Z Rheumatol; 2005 Apr; 64(3):170-6. PubMed ID: 15868334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
